A detailed history of Group One Trading, L.P. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 23,470 shares of MRSN stock, worth $49,756. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,470
Holding current value
$49,756
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.0 - $4.45 $46,940 - $104,441
23,470 New
23,470 $47,000
Q4 2023

Feb 14, 2024

SELL
$1.11 - $2.34 $12,195 - $25,709
-10,987 Reduced 26.12%
31,081 $72,000
Q3 2023

Nov 09, 2023

SELL
$1.06 - $3.91 $125,329 - $462,298
-118,235 Reduced 73.76%
42,068 $53,000
Q2 2023

Aug 09, 2023

BUY
$3.08 - $9.55 $487,268 - $1.51 Million
158,204 Added 7537.11%
160,303 $527,000
Q1 2023

May 12, 2023

BUY
$4.0 - $7.02 $8,396 - $14,734
2,099 New
2,099 $8,000
Q3 2022

Nov 09, 2022

SELL
$4.63 - $8.0 $5,931 - $10,248
-1,281 Reduced 63.32%
742 $5,000
Q2 2022

Aug 11, 2022

SELL
$2.84 - $5.0 $45,724 - $80,500
-16,100 Reduced 88.84%
2,023 $9,000
Q1 2022

May 12, 2022

BUY
$3.74 - $6.63 $62,832 - $111,384
16,800 Added 1269.84%
18,123 $72,000
Q4 2021

Feb 11, 2022

SELL
$5.48 - $9.86 $13,842 - $24,906
-2,526 Reduced 65.63%
1,323 $8,000
Q3 2021

Nov 12, 2021

BUY
$8.56 - $14.47 $32,947 - $55,695
3,849 New
3,849 $36,000
Q2 2021

Aug 10, 2021

SELL
$13.28 - $18.07 $117,793 - $160,280
-8,870 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$15.31 - $26.52 $74,452 - $128,966
4,863 Added 121.36%
8,870 $144,000
Q4 2020

Feb 10, 2021

BUY
$16.84 - $27.59 $67,477 - $110,553
4,007 New
4,007 $107,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $206M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.